Tocilizumab (anti–IL-6 agent) has been successful in controlling disease activity and improving proteinuria in patients with FMF-associated amyloidosis and also in few TRAPS and HIDS/MKD patients resistant to anti-TNF and/or anti–IL-1 agents. Here, IL6 is linked to mevalonic aciduria.